← boardnext 2028-01next 2029-05-01next 2029-07-01
FATE
Fate Therapeuticsdistress 3/10 · well-funded / low risk$2.52-2%today-19% from 52w high
Oncology 3
Lead: Lupus Nephritis · target CD19 · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$175M
Runway
1.7 yrs
Shares 1y
+1%
Price & events
+101.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
-7.7%
1W
+16.7%
1M
+90.9%
3M
+108.3%
6M
+96.9%
1Y
-54.8%
2Y
-97.1%
5Y
-97.2%
All
Overview
- Market Cap
- $293.73M
- Volume
- 347.41K
- 52 Week Range
- $0.92 – $3.11
- Total Shares
- 116.56M
- Float Shares
- 101.86M
- Short %
- 7.23%
- % Held by Insiders
- 1.17%
- % Held by Institutions
- 73.03%
- RVOL
- 0.09x
- Beta
- 2.52
Pipeline stages · 5 programs
FT836, Paclitaxel, Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FT825, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FT819
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FT522, Rituximab, Cyclophosphamide, Fludarabine, BendamustineCD20
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-01-31 | Phase 1 | FT836, Paclitaxel, Cetuximab | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma | — | recruiting |
| 2029-05-01 Estimated 50% readout ~2029-05-31 | Phase 1 | FT825, Fludarabine, Cyclophosphamide | Advanced Solid Tumor | — | recruiting |
| 2029-07-01 Estimated 50% readout ~2029-08-15 | Phase 2 | FT819rmat | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | — | not yet recruiting |
| 2026-05 | Phase 1 | FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 0 | withdrawn |
| 2025-06-18 | Phase 1 | FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustinermat | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia | 54 | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-06 | Phase 1 | FT522, Rituximab, Cyclophosphamide, Fludarabine, Bendamustine | Relapsed/Refractory B-Cell Lymphoma | 20 | completed |
Catalyst news & presentations · 3
- 2026Guided 40%trial initiationsecondaryFT819 · Goal to initiate pivotal study in 2026.SEC 8-K
- 2H2026Guided 55%trial initiationsecondaryPhase 1FT839 · Phase 1 trial initiation for FT839 in autoimmune indicationsSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $5 (+115% upside) · 9 analysts
- 2026-06-08HC Wainwright & Co.Buy
- 2026-05-04HC Wainwright & Co.Buy
- 2025-10-31HC Wainwright & Co.Neutral → Buy
- 2025-10-27WedbushNeutral → Outperform
- 2025-10-27NeedhamHold
- 2025-08-13Wells FargoEqual-Weight
Competitors — CD19
Recent news
- 2026-07-21Feds To Decide Fate Of $2 Billion California Plan To Fund Medi-Cal - Word & Brown General Agency
- 2026-07-21Biggest US Power Grid Faces Possible Breakup as FERC Weighs Fate - Bloomberg.com
- 2026-07-21EXCLUSIVE: Judge Licht Is Deciding Shekarchi’s Fate for Supreme Court… - Go Local Prov
- 2026-07-21HRW urges Turkey to reveal fate of Turkmen activists missing for a year - Stockholm Center for Freedom
- 2026-07-21ICC vote to decide fate of chief prosecutor Karim Khan - thenationalnews.com
- 2026-07-21As He Hears Fate, Cartel Boss Speaks: 'Violence Must End' - Newser
- 2026-07-21Rin Tohsaka in Honkai Star Rail - Gameplay Revealed for Fate/stay night Character - ixbt.games
- 2026-07-21Arash Mahmoudi’s Fate Remains Unknown 10 Days Into His Detention - Hana Human Rights Organization
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.